/
Oncology
Metastatic Colorectal Cancer
138
Pipeline Programs↗
207
Active Trials↗
118
Companies Involved↗
Metastatic Colorectal Cancer is a highly competitive landscape with 138 programs across 118 companies. The most active players are Shanghai Henlius Biotech, BioNTech, AbbVie. 38 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical30
Phase 16
Phase 264
Phase 338
Approved
No programs
Analysis
Modality Breakdown
74%
Small molecule
98 of 133 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 133 classified programs, each share of the total. Modality classified for 98% of 138 pipeline programs.
Analysis
Trial Status
954
clinical trials
Completed449 · 47%
Unknown status136 · 14%
Recruiting119 · 12%
Terminated118 · 12%
Not yet recruiting46 · 5%
Active, not recruiting42 · 4%
Other44 · 5%
Clinical Trials
Trial Activity
954 trials
Page 1 of 64
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)